Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 3Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Stomach Neoplasms 3Adenocarcinoma 3Neoplasms 2Gastric Cancer Adenocarcinoma Metastatic 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Blood Specimen Collection 38pembrolizumab 36Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 18Exercise 17Carboplatin 16Nivolumab 15atezolizumab 14Cisplatin 14Drug Therapy 13Paclitaxel 12Fluorouracil 12Cyclophosphamide 12Cetuximab 12Trastuzumab 10Leucovorin 10Docetaxel 10Dexamethasone 10Pemetrexed 9Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × zolbetuximab × Clear all
NCT06901531 2026-06-05

LUCERNA

Astellas Pharma Inc

Phase 3 Recruiting
500 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT06902545 2026-03-11

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Astellas Pharma Inc

Recruiting
377 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡